{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T04:21:07Z","timestamp":1744258867041,"version":"3.40.4"},"reference-count":0,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"3","license":[{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Alerg Mex"],"abstract":"<jats:p>Background: Trimethoprim with sulfamethoxazole (TMP-SMX) is the drug of choice for the prophylaxis of AIDS-associated comorbidities.\nObjective: To compare the efficacy and safety of two schemes of desensitization to TMP-SMX in HIV-positive patients.\nMethods: A study was conducted from March 2018 to October 2019; it included HIV-positive patients who presented an adverse skin reaction to TMP-SMX; fifteen of them received desensitization scheme 1, which lasted ten days, and five patients received scheme 2, which lasted six hours.\nResults: The average age of the patients who received scheme 1 was of 27.4 \u00b1 5.7 years, while the average age of patients who received scheme 2 was of 33.6 \u00b1 8 years. At baseline, the demographic, clinical, and immunological variables did not show significant differences between both groups (p&gt; 0.05). In both groups, an efficacy of 100% was obtained and, in terms of safety, only three patients in group 1 presented rash and pruritus, however, the procedure was not suspended; the previous tolerated dose was resumed and, subsequently, the desensitization procedure continued.\nConclusions: Both schemes of desensitization to TMP-SMX showed efficacy and safety in HIV-positive patients, who frequently present adverse reactions to these medications.<\/jats:p>","DOI":"10.29262\/ram.v67i3.745","type":"journal-article","created":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T02:42:23Z","timestamp":1611974543000},"page":"237-244","source":"Crossref","is-referenced-by-count":2,"title":["Eficacia y seguridad de dos esquemas de desensibilizaci\u00f3n a trimetoprima con sulfametoxazol en pacientes positivos a VIH","The efficacy and safety of two schemes of desensitization to trimethoprim-sulfamethoxazole in HIV-positive patients"],"prefix":"10.29262","volume":"67","author":[{"given":"Eleazar","family":"Mancilla-Hern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria del Rocio","family":"Hern\u00e1ndez-Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11808","published-online":{"date-parts":[[2021,1,20]]},"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"link":[{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/745\/2347","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/745\/1356","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/745\/2347","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:10:48Z","timestamp":1744215048000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,12,24]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v67i3.745","relation":{},"ISSN":["2448-9190","0002-5151"],"issn-type":[{"type":"electronic","value":"2448-9190"},{"type":"print","value":"0002-5151"}],"subject":[],"published":{"date-parts":[[2021,1,20]]}}}